VistaScan Mobile UltraSound Platform Receives 510(k) Clearance


The VistaScan mobile ultrasound platform from Emagine Solutions Technology can be used via an app and connect directly to a clinician's cell phone or tablet.

fda logo

A new mobile ultrasound device has received 510(k) clearance from the US Food and Drug Administration (FDA), adding another tool to armamentarium available to care providers and allowing for ultrasounds in a broader range of environments.

The VistaScan mobile ultrasound platform, which is produced by Emagine Solutions Technology, is designed to allow for ultrasounds to be performed quickly with the use of a cell phone or tablet and at a fraction of the cost of a cart ultrasound machine, according to a statement from the company.

"Receiving FDA clearance is excellent validation of our technology and demonstrates the role handheld ultrasound will play in enhancing patient care," commented Courtney Williams, co-founder and CEO of Emagine Solutions Technology, in the aforementioned statement.

The mobile ultrasound platform works via a VistaScan app on the clinician’s tablet or cell phone and plugs into a compatible FDA-cleared ultrasound probe. According to the statement from Emagine Solutions, the platform should allow for more efficient treatment and diagnosis even in places outside of a typical clinical setting.

It is unclear when the VistaScan mobile ultrasound platform will be available in US markets. However, interested parties can preorder the product or sign up for demonstrations on the VistaScan website.

"The velocity and complexity of modern medicine is becoming overwhelming, and putting the power of ultrasound into the pockets of clinicians so they can use it for real-time diagnosis right at the bedside is liberating and transformative," added Berndt Schmit, MD, section chief of emergency radiology at Banner University Medical Center at the University of Arizona and president of Humanitarian Radiology Development Corps, in a statement.

Related Videos
Elizabeth Cerceo, MD | Credit: ACP
Elizabeth Cerceo, MD | Credit: ACP
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
© 2024 MJH Life Sciences

All rights reserved.